Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19245138 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL25182328 | 0.93 | BTK (0.35) | BTK | |
| SCHEMBL31407418 | 0.93 | BTK (0.38) | BTK | |
| SCHEMBL25182277 | 0.93 | BTK (0.38) | BTK | |
| SCHEMBL31407713 | 0.93 | BTK (0.35) | BTK | |
| SCHEMBL19328219 | 0.92 | GAA (0.36) | BTK | |
| SCHEMBL17493774 | 0.92 | GAA (0.36) | BTK | |
| SCHEMBL19088462 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19066725 | 0.84 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21492499 | 0.83 | CA12 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| EP-2310402-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2011-04-20 | — | — | EP | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| WO-2009155709-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | CHRNB2 3773/4885CHRNB4 4157/4885CHRNA3 3567/4885 |
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | CHRNB2 1379/4885CHRNB4 1474/4885CHRNA3 2142/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CHRNB2 4322/4885CHRNB4 4431/4885CHRNA3 3735/4885 |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC7 | CHRNB2 3988/4885CHRNB4 4121/4885CHRNA3 4530/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | CHRNB2 4666/4885CHRNB4 4814/4885CHRNA3 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.